122 related articles for article (PubMed ID: 2015717)
1. Soluble factors released by the target organ enhance the urokinase-type plasminogen activator activity of metastatic tumor cells.
Bal de Kier Joffé E; Alonso DF; Puricelli L
Clin Exp Metastasis; 1991; 9(1):51-6. PubMed ID: 2015717
[TBL] [Abstract][Full Text] [Related]
2. Urokinase-type plasminogen activator activity increases during the growth of two murine mammary adenocarcinomas with different metastasizing abilities.
Pereyra-Alfonso S; Solarz GR; Bal de Kier Joffé E
Clin Exp Metastasis; 1992 Nov; 10(6):395-401. PubMed ID: 1451349
[TBL] [Abstract][Full Text] [Related]
3. Correlation between urokinase-type plasminogen activator production and the metastasizing ability of two murine mammary adenocarcinomas.
Pereyra-Alfonso S; Haedo A; Bal de Kier Joffé E
Int J Cancer; 1988 Jul; 42(1):59-63. PubMed ID: 3134309
[TBL] [Abstract][Full Text] [Related]
4. Apoptotic cell death in mammary adenocarcinoma cells is prevented by soluble factors present in the target organ of metastasis.
Ladeda V; Adam AP; Puricelli L; Bal de Kier Joffé E
Breast Cancer Res Treat; 2001 Sep; 69(1):39-51. PubMed ID: 11759827
[TBL] [Abstract][Full Text] [Related]
5. GM-CSF secreted by murine adenocarcinoma cells modulates tumor progression and immune activity.
Diament MJ; Stillitani MI; Puricelli L; Bal de Kier-Joffe E; Klein S
Oncol Rep; 2003; 10(5):1647-52. PubMed ID: 12883753
[TBL] [Abstract][Full Text] [Related]
6. Varying patterns of expression of insulin-like growth factors I and II and their receptors in murine mammary adenocarcinomas of different metastasizing ability.
Guerra FK; Eijan AM; Puricelli L; Alonso DF; Bal de Kier Joffé E; Kornblihgtt AR; Charreau EH; Elizalde PV
Int J Cancer; 1996 Mar; 65(6):812-20. PubMed ID: 8631597
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of human tumor cell-associated fibrinolysis by vascular bovine smooth muscle cells.
Laug WE
J Natl Cancer Inst; 1985 Aug; 75(2):345-52. PubMed ID: 3860687
[TBL] [Abstract][Full Text] [Related]
8. Effect of hyperthermia on the viability and the fibrinolytic potential of human cancer cell lines.
Fukao H; Ikeda M; Ichikawa T; Inufusa H; Okada K; Ueshima S; Matsuo O
Clin Chim Acta; 2000 Jun; 296(1-2):17-33. PubMed ID: 10807968
[TBL] [Abstract][Full Text] [Related]
9. Secretion of plasminogen activators by human colorectal and gastric tumor explants.
Harvey SR; Lawrence DD; Madeja JM; Abbey SJ; Markus G
Clin Exp Metastasis; 1988; 6(6):431-50. PubMed ID: 3409559
[TBL] [Abstract][Full Text] [Related]
10. Correlation between urokinase-type plasminogen activator production and the metastatic ability of human rectal cancer cells.
Marutsuka K; Suzumiya J; Kataoka H; Komada N; Koono M; Sumiyoshi A
Invasion Metastasis; 1991; 11(4):181-91. PubMed ID: 1765431
[TBL] [Abstract][Full Text] [Related]
11. Urokinase synthesis and binding by glomerular epithelial cells in culture.
Rondeau E; Ochi S; Lacave R; He CJ; Medcalf R; Delarue F; Sraer JD
Kidney Int; 1989 Oct; 36(4):593-600. PubMed ID: 2554052
[TBL] [Abstract][Full Text] [Related]
12. Differential production of angiostatin by concomitant antitumoral resistance-inducing cancer cells.
Binda MM; Matar P; González AD; Rozados VR; Gervasoni SI; Scharovsky OG; Bonfil RD
Int J Cancer; 2002 Jul; 100(1):14-21. PubMed ID: 12115581
[TBL] [Abstract][Full Text] [Related]
13. Impairment of fibrinolysis during the growth of two murine mammary adenocarcinomas.
Alonso DF; Farías EF; Bal de Kier Joffé E
Cancer Lett; 1993 Jul; 70(3):181-7. PubMed ID: 8353814
[TBL] [Abstract][Full Text] [Related]
14. In vitro urokinase type plasminogen activator levels and total plasminogen activator activity in squamous cell carcinomas of the head and neck.
Petruzzelli GJ; Snyderman CH; Johnson JT
Arch Otolaryngol Head Neck Surg; 1994 Sep; 120(9):989-92. PubMed ID: 8074827
[TBL] [Abstract][Full Text] [Related]
15. Modulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression by U-937 mononuclear phagocytes. Effects of 1 alpha, 25-dihydroxyvitamin D3 and phorbol ester.
Gyetko MR; Webb AC; Sitrin RG
J Immunol; 1988 Oct; 141(8):2693-8. PubMed ID: 3139763
[TBL] [Abstract][Full Text] [Related]
16. Fibrinolysis activity promotes tumor invasiveness of B16 melanoma cell lines through a reconstituted gel matrix.
Mimura K; Sueishi K; Yasunaga C; Tanaka K
Invasion Metastasis; 1992; 12(1):24-34. PubMed ID: 1380952
[TBL] [Abstract][Full Text] [Related]
17. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
18. Human hepatoma cell line plasminogen activator.
Levin EG; Fair DS; Loskutoff DJ
J Lab Clin Med; 1983 Oct; 102(4):500-8. PubMed ID: 6311924
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D3 and calcipotriol decrease extracellular plasminogen activator activity in cultured keratinocytes.
Koli K; Keski-Oja J
J Invest Dermatol; 1993 Nov; 101(5):706-12. PubMed ID: 8228332
[TBL] [Abstract][Full Text] [Related]
20. Effect of host-organ environment on the in vivo and in vitro behavior of a murine mammary adenocarcinoma.
Puricelli L; Gómez DE; Vidal MC; Eiján AM; Spinelli O; Alonso DF; de Lustig ES; Bal de Kier Joffé E
Tumour Biol; 1994; 15(5):284-93. PubMed ID: 7991989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
